As to other therapeutics developed targeting mutant KRAS, the FDA granted sotorasib, a KRAS G12C small molecule inhibitor priority review status in 2021 for the treatment of non–small cell lung cancer patients with KRAS G12C mutation. Here, KRAS is linked to lung cancer.